Abivax stock price target raised to $114 from $95 at JMP Securities

Investing.com - JMP Securities has raised its price target on Abivax (NASDAQ:ABVX) to $114.00 from $95.00 while maintaining a Market Outperform rating on the stock. The new target aligns with the broader analyst consensus, as tracked by InvestingPro, which shows targets ranging from $95 to $116, suggesting further upside potential from the current trading price of $82.55.

The firm expects Abivax to present additional analyses of its drug obefazimod, including its efficacy in advanced treatment, advanced treatment-naïve patients, refractory, and JAK-inhibitor failed patients.

JMP believes these results could serve as a differentiating feature for obefazimod, highlighting its effectiveness in the most severe ulcerative colitis patient population.

The price target increase reflects JMP’s updated model incorporating Abivax’s first-half 2025 financial results and the July equity financing, as well as an increased peak penetration rate from 20% to 22%, which raises U.S. peak sales estimates in ulcerative colitis from $2.6 billion to $2.9 billion.

Following the equity financing, JMP estimates Abivax has a pro forma cash position of approximately $800 million, which it believes will support operations into the fourth quarter of 2027.

In other recent news, Abivax SA has announced the launch of a $400 million public offering of American Depositary Shares, which aims to expand its financial capabilities. This move comes alongside Piper Sandler’s decision to raise Abivax’s stock price target to $112, citing promising Phase 3 data for obefazimod in treating ulcerative colitis. The firm has adjusted its financial models to reflect a significant revenue potential in early-line UC treatment, projecting €2,656 million in US revenue by 2035. Additionally, Guggenheim has maintained a Buy rating on Abivax, supported by promising data from Phase IIb readouts for competing inflammatory bowel disease treatments.

Meanwhile, Abivax is set to present its Phase 3 data on obefazimod at the United European Gastroenterology Congress next month. On a related note, JMP Securities has reiterated its Market Outperform rating for Rapport Therapeutics, maintaining a price target of $77. The research firm remains optimistic about Rapport’s prospects following strong clinical trial results. These recent developments highlight the ongoing activities and analyst perspectives surrounding Abivax and Rapport Therapeutics .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.